BACHEM
LIVE

Serial Number

79147297

Owner

BACHEM HOLDING AG

Attorney

Alex R. Sluzas

Filing Date

Apr 8, 2014

Add to watchlist:

No watchlists yet
View on USPTO

BACHEM Trademark

Serial Number: 79147297 • Registration: 4741291

BACHEM is a trademark filed by BACHEM HOLDING AG on April 8, 2014. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

BACHEM HOLDING AG (10 trademarks)

HAUPTSTRASSE 144
BUBENDORF 4416 , CH

Entity Type: 03

Trademark Details

Filing Date

April 8, 2014

Registration Date

May 26, 2015

Published for Opposition

March 10, 2015

Goods & Services

Pharmaceutical and veterinary products, namely, pharmaceutical preparations for use in the treatment of bleeding, premature labor, pulmonary hypertension, erectile disfunction, coronary syndromes, prostate cancer, endometriosis, central precocious puberty, uterine myoma, osteoporosis, hypercalcernia, Paget's disease, reflex sympathetic dystrophy, nocturnal enureses, central diabetes insipidus, polyuria, polydipsia, hemophilia A, von Willebrand disease, unstable angina, myocardial infarction, hypoglycemia, ovarian follicular cysts, cryptochism, breast cancer, growth hormone deficiency, acromegaly, carcinoid syndrome, thyrotrophic adenomas, diabetes II, VIPosmas, ulcer bleeding, hemorrhagic gastritis, postoperative pancreatic and duodenal fistulae, variceal hemorrhage, neurological diseases, rheumatic diseases, skin diseases, diseases of the intestinal tract, cancer, conjunctivitis, glaucoma, ocular hypertension, Parkinson's disease, transfusion-induced hemosiderosis, candidasis, dermatophytosis, pityriasis, congenital homocystinuria, hyperammonaemia, hepatic encephalopathy, ischemic heart disease, chorioretinal vascular disorders, hypertension, endema, insomnia, bipolar disorder, and schizophrenia; pharmaceutical preparations for use in the diagnosis of gastrinoma; veterinary preparations for use in the induction of ovulation in estrous mares, and reproduction control in dogs and cats; pharmaceutical preparations for use in the diagnosis of Cushing's syndrome, hypothalamic-pituitary-gonadal axis function, growth hormone deficiency, pancreatic exocrine dysfunction, gastrinoma, and adrenocortical insufficiency; dietetic food and substances for medical or veterinary use, namely, taste-modulating food additives in the nature of peptides for medical use, appetite suppressors for medical use; food supplements for humans and animals; fungicides; herbicides

Chemicals for use in industry and science, namely, amino acids, peptides, reagents for peptide synthesis, amino acid derivatives, cytokines, enzyme inhibitors, enzyme substrates, growth factors, peptide substrates, all for use as scientific and laboratory research reagents in the field of medicine and molecular biology; pharmaceutical intermediates for use in the further manufacture of pharmaceuticals; chemical products used for preserving foodstuffs

Filing History

TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
Jan 12, 2026 EROP
NEW REPRESENTATIVE AT IB RECEIVED
Nov 30, 2025 NREP
PROOF OF USE INTERIM ACTION ISSUED
Jul 12, 2025 PUMI
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 10, 2025 APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 4, 2025 APRE
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
May 23, 2025 EROP
OFFICE ACTION ISSUED POU1
Jun 25, 2024 PUM1
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 25, 2024 APRE
TEAS SECTION 71 RECEIVED
Jun 18, 2024 ES71
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
May 26, 2024 REM4
INTERNATIONAL REGISTRATION RENEWED
Apr 18, 2024 RNWL
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Mar 22, 2021 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Mar 22, 2021 C75A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 22, 2021 APRE
TEAS SECTION 71 & 15 RECEIVED
Feb 18, 2021 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
May 26, 2020 REM3
NEW REPRESENTATIVE AT IB RECEIVED
Feb 1, 2019 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Oct 30, 2015 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 24, 2015 FICS
FINAL DISPOSITION PROCESSED
Sep 24, 2015 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 26, 2015 FICR
REGISTERED-PRINCIPAL REGISTER
May 26, 2015 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 10, 2015 NPUB
PUBLISHED FOR OPPOSITION
Mar 10, 2015 PUBO
NOTIFICATION PROCESSED BY IB
Mar 6, 2015 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 18, 2015 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 18, 2015 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 18, 2015 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jan 30, 2015 PREV
ASSIGNED TO LIE
Jan 29, 2015 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 9, 2015 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 9, 2015 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 9, 2015 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 9, 2015 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 9, 2015 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 8, 2015 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 8, 2015 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 8, 2015 TROA
REFUSAL PROCESSED BY IB
Aug 8, 2014 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 23, 2014 RFCS
REFUSAL PROCESSED BY MPU
Jul 23, 2014 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 18, 2014 RFCR
NON-FINAL ACTION WRITTEN
Jul 17, 2014 CNRT
ASSIGNED TO EXAMINER
Jul 17, 2014 DOCK
APPLICATION FILING RECEIPT MAILED
Jun 3, 2014 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 30, 2014 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 29, 2014 REPR